---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-042966"
form_type: "8-K"
ticker: "CTXR"
cik: "0001506251"
company_name: "Citius Pharmaceuticals, Inc."
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T00:45:13.741446+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Citius Pharma Q2 net loss $8.5M; LYMPHIR PDUFA Aug 13, Mino-Lok data due Q2

## Summary
- Cash $12.6M at Mar 31; $15M April offering extends runway through Dec 2024.
- LYMPHIR BLA accepted with PDUFA target date August 13, 2024.
- Mino-Lok Phase 3 topline results anticipated in calendar Q2 2024.
- Merger of oncology sub with TenX (TENK) progressing; pending SEC/TENK approval.
- Net loss $8.5M ($0.05/shr) vs $10.5M loss a year ago; R&D expense down.

## SEC filing metadata
- accession: 0001213900-24-042966
- form_type: 8-K
- ticker: CTXR
- cik: 0001506251
- company_name: Citius Pharmaceuticals, Inc.
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506251/000121390024042966/0001213900-24-042966-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506251/000121390024042966/ea0206086-8k_citius.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-042966
- JSON: https://secwatch.observer/filing/0001213900-24-042966.json
- Plain text: https://secwatch.observer/filing/0001213900-24-042966.txt

## Key facts
- Earnings Releases
  Citius Pharmaceuticals, Inc. reported fiscal second quarter 2024 ended March 31, 2024 results: net income Net loss was $8.5 million and $17.8 million, or ($0.05) and ($0.11) per share for the three and six months ended March 3, EPS ($0.05) and ($0.11) per share for the three and six months ended March 31, 2024.
  - Period: fiscal second quarter 2024 ended March 31, 2024
  - Net income: Net loss was $8.5 million and $17.8 million, or ($0.05) and ($0.11) per share for the three and six months ended March 3
  - EPS: ($0.05) and ($0.11) per share for the three and six months ended March 31, 2024
  - Result: reported results
  source text: Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business Update
  evidence_url: https://www.sec.gov/Archives/edgar/data/1506251/000121390024042966/0001213900-24-042966-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.